A Multicenter Study Evaluating the Safety and Tolerability of Intravenous rhMBL in Liver Transplant Recipients.

NCT ID: NCT00415311

Last Updated: 2011-08-09

Basic Information

• Recruitment Status: TERMINATED
• Clinical Phase: PHASE1
• Total Enrollment: 24 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2006-12-31
• Study Completion Date: 2009-12-31

Brief Summary

This is a multicenter, open-label, randomized, Phase 1B study evaluating liver transplant recipients receiving rhMBL (2 cohorts) or without rhMBL (1 cohort).

Detailed Description

This is a multicenter, open-label, randomized, Phase 1B study evaluating liver transplant recipients receiving rhMBL (2 cohorts) or without rhMBL (1 cohort).

Patients will have received an orthotopic liver transplant (OLT) or a living related donor (LRD) liver transplant. Patients in all cohorts are to receive immunosuppressant therapy and anti-infectious prophylactic supportive therapy according to institutional standards.

The donor's mannose-binding lectin (MBL) genotype will be evaluated to determine the liver transplant recipient's study eligibility. For recipients receiving an OLT, a sample of liver tissue or lymph nodes will be collected from the donor liver at the time of organ harvest for MBL genotyping. For recipients receiving a LRD transplant, the MBL genotype of the LRD will be determined in a companion protocol, "Screening Protocol to Evaluate Mannose-Binding Lectin (MBL) Genotype in Living Related Donors for Liver Transplant Recipients." A recipient whose donor has an A/O or O/O MBL genotype will be eligible to participate in this study.

Patients will be randomized in a 2:2:1 ratio to receive up to 8 intravenous (i.v.) infusions of rhMBL at a dose of 0.5 or 1.0 mg/kg, or to receive no rhMBL, respectively. Approximately 20 patients will be treated in each of the 2 rhMBL arms, and approximately 10 patients will be treated with standard immunosuppressive agents and anti-infectious prophylaxis but not with rhMBL.

Cohort 1

• Number of Patients 20
• rhMBL (mg/kg) 0.5

Cohort 2

• Number of Patients 20
• rhMBL (mg/kg) 1.0

Cohort 3

• Number of Patients 10
• rhMBL (mg/kg) None

Conditions

Liver Transplantation

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

0 mg/kg

Group Type: OTHER

Intravenous Recombinant Human Mannose-Binding Lectin (rhMBL)

Intervention Type: DRUG

Intravenous(i.v.) administration for 8 weeks. Patients will be randomized to one of three cohorts: 0 mg/kg; 0.5 mg/kg, or 1.0 mg.kg

0.5 mg/kg

Group Type: OTHER

Intravenous Recombinant Human Mannose-Binding Lectin (rhMBL)

Intervention Type: DRUG

Intravenous(i.v.) administration for 8 weeks. Patients will be randomized to one of three cohorts: 0 mg/kg; 0.5 mg/kg, or 1.0 mg.kg

1.0 mg/kg

Group Type: OTHER

Intravenous Recombinant Human Mannose-Binding Lectin (rhMBL)

Intervention Type: DRUG

Intravenous(i.v.) administration for 8 weeks. Patients will be randomized to one of three cohorts: 0 mg/kg; 0.5 mg/kg, or 1.0 mg.kg

Interventions

Intravenous Recombinant Human Mannose-Binding Lectin (rhMBL)

Intravenous(i.v.) administration for 8 weeks. Patients will be randomized to one of three cohorts: 0 mg/kg; 0.5 mg/kg, or 1.0 mg.kg

Intervention Type: DRUG

Intravenous Recombinant Human Mannose-Binding Lectin (rhMBL)

Intravenous(i.v.) administration for 8 weeks. Patients will be randomized to one of three cohorts: 0 mg/kg; 0.5 mg/kg, or 1.0 mg.kg

Intervention Type: DRUG

Intravenous Recombinant Human Mannose-Binding Lectin (rhMBL)

Intravenous(i.v.) administration for 8 weeks. Patients will be randomized to one of three cohorts: 0 mg/kg; 0.5 mg/kg, or 1.0 mg.kg

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

• Capable of understanding the protocol requirements and risks and providing written informed consent.
• Scheduled to undergo OLT or LRD liver transplantation (single organ). Split grafts will not be allowed from OLT donors.
• Donor has an MBL genotype of A/O or O/O.
• Age ≥18 years old.
• Willing to receive transfusions of blood products.

Any patient who has given informed consent to participate in the clinical study and who meets all entry criteria for the study may participate in the genetic part of the study.

Exclusion Criteria

• Concurrent serious medical illness, in the judgment of the principal investigator (PI), which could potentially interfere with protocol compliance.
• Positive screening pregnancy test or is breast-feeding.
• Female or male patient of reproductive capacity unwilling to use methods appropriate to prevent pregnancy during this study.
• Any condition that, in the opinion of the PI or Enzon makes the patient unsuitable for the study.
• Current participation in another clinical study with an investigational agent and/or use of an investigational drug (not including investigational use of an approved drug) in the 30 days before the first dose of rhMBL.
• Prior liver transplants.
• Systemic chemotherapy within 1 year before liver transplantation.
• Serum creatinine >5 mg/dL.

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Enzon Pharmaceuticals, Inc.

INDUSTRY

Sponsor Role: lead

Responsible Party

Enzon Pharmaceuticals, Inc

Principal Investigators

Alison Freifeld, MD

Role: PRINCIPAL_INVESTIGATOR

University of Nebraska Medical Center, 985400 Nebraska Medical Center, Omaha, NE 68198-5400

Locations

University of California San Francisco

San Francisco, California, United States

Nebraska Medical Center

Omaha, Nebraska, United States

Mount Sinai School of Medicine

New York, New York, United States

Vanderbilt University

Nashville, Tennessee, United States

Countries

United States

Other Identifiers

EZN-2232-02

Identifier Type: -

Identifier Source: org_study_id